At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 147 enrolled
Drug / intervention
Paricalcitol injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis
In Brief
A Phase 4 clinical trial evaluating Paricalcitol injection and Paricalcitol capsules for Secondary Hyperparathyroidism and Dialysis. Completed, enrolled 147 participants across 12 sites.
Detailed Summary
Prospective, non-randomized, multi-center study to assess the efficacy and safety of paricalcitol injection or oral administered over 6 months to patients with secondary hyperparathyroidism on dialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSecondary Hyperparathyroidism, Dialysis
CountriesMexico
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedOct 2007
Primary CompletionJul 2010
TodayJul 2026
First PostedOct 2, 2007
Enrollment StartSep 1, 2007
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.8 years ago
Interventions
Paricalcitol injectiondrug
Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
Paricalcitol capsulesdrug
Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly